Although biological mechanisms of acquired resistance to EGFR-TKIs have been extensively explored in several in vitro models, the molecular mechanisms involved in the resistance of NSCLC cells exposed to suboptimal/intermittent doses of EGFR-TKIs have not been fully elucidated yet. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.